


Gastroparesis Drugs Market | Botulinum toxin injection segment is expected to grow at a CAGR of 5.6% by 2023

Gastroparesis Drugs Market Expected to Reach \$6,486 Million, Globally, by 2023

PORTLAND, OREGON, UNITED STATE, March 31, 2022 /EINPresswire.com/ -- The global gastroparesis drugs market is segmented on the basis of drug class, disease type, distribution channel, and region. Based on drug class, the market is divided into prokinetic agents, antiemetic agents, and botulinum toxin injections. By disease type, it is classified into diabetic gastroparesis, idiopathic



gastroparesis, postsurgical gastroparesis, and others. Depending on distribution channel, it is categorized into hospitals, pharmacies, clinics, and e-commerce. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

According to a new report published by Allied Market Research, titled, Gastroparesis Drugs Market, by Drug Class, Disease Type, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global gastroparesis market was valued at \$4,667 million in 2016, and is projected to reach \$6,486 million at a CAGR of 4.7% from 2017 to 2023.

Download Sample Report: https://www.alliedmarketresearch.com/request-sample/4153

Key Market Segments

BY DISTRIBUTION CHANNEL Hospitals Pharmacies Clinics E-commerce By Disease Type
Diabetic Gastroparesis
Idiopathic Gastroparesis
Post-surgical Gastroparesis
Others

By Drug Class Prokinetic Agents Antiemetic Agents

Botulinum Toxin Injections Key findings of the Gastroparesis Drugs Market:

Prokinetic agents segment accounted for more than four-fifths share of the global gastroparesis drugs market in 2016.

Botulinum toxin injection segment is expected to grow at a CAGR of 5.6% from 2017 to 2023. Idiopathic gastroparesis segment accounted for around 34.9% share of the global gastroparesis drugs market in 2016.

Hospitals accounted for nearly two-fifths share of the global gastroparesis drugs market in 2016.

Pharmacies segment is expected to grow at a CAGR of 5.0% from 2017 to 2023 North America was the leading revenue contributor to the global gastroparesis drugs market, accounting for nearly one-third of the global market. This is attributed to the early approval of gastroparesis drugs and high use of these drugs due to rise in incidence of gastroparesis. However, Asia-Pacific is expected to grow at the highest CAGR of 5.5% during the study period, due to increase in affordability, surge in healthcare expenditure, and rise in awareness toward gastroparesis drugs.

The major factors that drive the growth of the global gastroparesis drugs market are rise in number of surgeries that may lead to postoperative gastroparesis, increase in diabetic population, introduction of novel drugs, and surge in geriatric population. However, side effects associated with gastroparesis drugs and time-consuming regulatory approvals are expected to restrain the market growth. Conversely, huge untapped market potential in the emerging countries, such as China and India, and development of novel gastroparesis drugs are expected to provide lucrative opportunities to the market players.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/4153

Other Trending Reports:

Contrast Injector Systems Market

LAMEA IVD Market

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/567086305

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 IPD Group, Inc. All Right Reserved.